Article Text

other Versions

PDF
Correspondence
Success in adrenal venous sampling between two protocols: experience at a tertiary centre
  1. Mohammad Ali Husainy1,
  2. Cheng Fang1,
  3. Ana Nicolescu1,
  4. Dylan Lewis1,
  5. Pauline Kane1,
  6. Royce P Vincent2
  1. 1Department of Radiology, King's College Hospital NHS Foundation Trust, London, UK
  2. 2Department of Clinical Biochemistry (Viapath), King's College Hospital NHS Foundation Trust, London, UK
  1. Correspondence to Dr Mohammad Ali Husainy, Department of Radiology, King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, UK; m.husainy{at}nhs.net

Statistics from Altmetric.com

Adrenal venous sampling (AVS) is currently the best available confirmatory test for lateralising aldosterone production in proven primary aldosteronism (PA).1 AVS is an invasive procedure, which carries a small risk of complications, but requires skilled radiologist to obtain biochemically selective samples.2 The technical success rate of AVS has been cited up to 96% in specialised centres,3 whereas unsuccessful AVS is primarily due to failure in cannulating the right adrenal vein, because of its challenging anatomy. Furthermore, in spite of ‘radiologically successful’ cannulation of both adrenal veins, the samples obtained can still be non-diagnostic due to dilution and lack of selectivity.

Following a revision of our AVS protocol (both radiological and biochemical) in 2012, we assessed its impact on the success rate of the procedure. We carried out a retrospective review of all AVS performed in the interventional radiology department since 2008. Prior to 2012 (pre-2012 protocol), three interventional radiologist (IR) performed AVS in randomly allotted slots without cosyntropin stimulation using a size 5 French (Fr) SIM2 Glidecath (Terumo, Somerset, New Jersey) as the preferred catheter for cannulation. As per the revised protocol (post-2012 protocol), two IR (combined experience of >24 years) were designated to perform all AVS procedures and patients were booked as the first case in the morning list. All received cosyntropin bolus intravenously (250 μg in 5 mL of 0.9% saline) an …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.